Choice

IPO Report

"Subscribe for Long Term" to Lenskart Solutions Ltd.

Tech-driven, fast-growing eyewear brand with a premium valuation.



Lenskart Solutions Ltd.

Tech-driven, fast-growing eyewear brand with a premium valuation.

Choice

29th Oct. 2025

Salient features of the IPO:

- Lenskart Solutions Ltd. (LSL), Incorporated on May 19, 2008, is a
 technology-driven eyewear company with integrated operations across
 design, manufacturing, branding, and retailing of eyewear products. The
 company primarily offers prescription eyeglasses, sunglasses, contact
 lenses, and eyewear accessories. Operating through a direct-to-consumer
 model, LSL designs and sells a diverse range of products under its own
 brands and sub-brands.
- This public issue is a combination of fresh issue (Rs. 2,150cr) and OFS (Rs. 4,872.89 5,128.02cr). The company will not receive any proceeds from the OFS portion. From the fresh issue net proceeds, the company will be utilizing Rs. 272.62cr for capital expenditure towards set-up of new CoCo stores in India, Rs. 591.44cr for Expenditure for lease/rent/license agreements related payments for CoCo stores operated by the Company, in India, Rs. 213.37cr for Investing in technology and cloud infrastructure, and Rs. 320cr for Brand marketing and business promotion expenses for enhancing brand awareness. Residual proceeds will be used for general corporate purposes.

Key competitive strengths:

- Centralized Supply Chain and Manufacturing Processes
- Frame and Lens Engineering and Manufacturing Capabilities
- · Direct-to-consumer model
- Customer-Focused Product Design Capabilities
- · Lenskart Brand and Portfolio of Owned Sub-brands
- Omnichannel Retail Network
- Technology First Approach to Customer Experience and Operational Efficiency

Business strategy:

- Increase Markets' Penetration and, Expand Customer Access Across Channels
- Strengthen Manufacturing and Supply Chain Capabilities
- Continue to Innovate and Expand Product Portfolio
- Invest in New Technologies
- Continue to Enhance Customer Experience
- Continue to strengthen brand across markets

Risk and concerns:

- Depend on eyeware product to lenskart Gold member
- · Eyeware industry in India is largely unorganized
- Technology failures can adversely impact business operations
- Competition

Valuation Overview and IPO Rating

At the upper end of its price band, LSL is valued at an EV/Sales of 9.9× (TTM basis), which appears significantly high. While the company has posted steady topline growth, profitability remains weak, with a positive PAT mainly driven by other income and lower expenses. LSL holds a 4–6% market share in the prescription eyewear segment, dominated by unorganized players. Its average revenue per store has improved from Rs. 1.9cr to Rs. 2.4cr, supported by operational efficiencies and Al-driven technologies. Billionaire investor Radhakishan Damani has invested around Rs. 90cr in the company during its pre-IPO funding round. About 40% of its revenue comes from international markets. Given its strong growth potential but high valuation and profitability risks, this offering is best suited for investors with a higher risk appetite and a long-term investment horizon. Thus we assign a "Subscribe for Long Term" rating for this issue.

		7	29 th Oct. 2025		
Issue details					
Price band	Rs. 382	- 402 per shar	e		
Face value	Rs. 2	· ·			
Shares for fresh issue	5.348 -	5.628cr shares	;		
Shares for OFS	12.756	cr shares			
Fresh issue size	Rs. 2,1!				
OFS issue size		72.89 - 5,128.0	2cr		
OI 3 133UE 312E		- 18.385cr sha			
Total issue size	(Rs. 7,0	22.89 - 7,278.0	O2cr)		
Employee Reservation	0.0373 (Rs. 15	- 0.0392cr sha cr)	res		
Net issue size		- 18.345cr sha 07.89 - 7,263.0			
Bidding date	31st Oc	t 04 th Nov. 20	025		
Implied MCAP at higher price band	Rs. 69,	741.25cr			
Implied enterprise value at higher price band	Rs. 69,	703.56cr			
Book running lead manager	Compa India C Capital Market Capital Service	Mahindra Capit ny Ltd., Morga ompany Pvt. Lt Pvt. Ltd., Citigi ss India Pvt. Ltd Ltd., Intensive s Pvt. Ltd., Axis ensive Fiscal So	n Stanley d., Avendus roup Global l., Axis Fiscal s Capital Ltd.,		
Registrar	MHEG	Intime India Pv	rt 1+d		
Sector			rt. Ltu.		
Sector Lifestyle (Eyeware)					
Promoters	•	Bansal, Nehall nary and Sume			
	-				
Category	ercent of ssue (%)	Number	of shares		
QIB portion	75%	13.550 - 13.	759cr shares		
Non institutional	7070	10.000 10.	7000.0.1.0.00		
portion (Big)	10%	1.807 - 1.8	35cr shares		
Non institutional portion (Small)	5%	0.903 - 0.9	17cr shares		
Retail portion	10%	1.807 - 1.8	35cr shares		
Indicative IPO process time	line				
Finalization of basis of allot	ment	06th Nov	ı. 2025		
Unblocking of ASBA accour	nt	07 th Nov	ı. 2025		
Credit to demat accounts		07 th Nov	ı. 2025		
Commencement of trading		10 th Nov	ı. 2025		
Pre and post - issue shareh	olding pa	ttern Pre-issue	Post-issue		
Dromotor & promotor	_				
Promoter & promoter grou	þ	19.90%	17.71%		
Public		79.67%	81.87%		
Shares held by employee		0.43%	0.42%		
Non-promoter & Non-publi	С	0.00%	0.00%		
Total		100.00%	100.00%		
Retail application money a	t higher c	ut-off price pe	r lot		
Number of shares per lot		37			
Employee Discount		Rs. 19			
Application manay					
Application money		Rs. 14,874 pe	er lot		

Key Highlights of the Industry and the Company:

- LSL began its operations in India as an online business in 2010 and expanded into offline retail with its first store in New Delhi in 2013.
 Since then, the company has grown rapidly through both online and offline channels, establishing a strong presence across retail stores, websites, mobile applications, and other platforms. During the three months ended June 30, 2025, and the financial year 2025, LSL recorded transactions from 3.73 mn and 9.94 mn customer accounts, respectively, in India, selling 6.72 mn and 22.91 mn units of eyewear during the same periods. As of June 30, 2025, the company operated 2,137 stores across India, comprising 1,831 company-owned stores and 306 franchise-owned stores.
- According to the RHP, LSL operates in a highly fragmented eyewear market, where approximately 77% of India's prescription
 eyeglasses market (by value) is dominated by small, unorganised opticians as of FY25. The company stands out as the only vertically
 integrated retailer with a centralised supply chain among the leading large organised retailers of prescription eyeglasses, both in India
 and globally.
- LSL has developed a scalable and replicable business model by strategically investing in technology solutions, Al tools, and automation
 across key areas such as customer engagement, supply chain and post-order fulfillment, retail operations, and internal processes.
 These capabilities empower the company to deliver a superior customer experience while driving operational efficiency at scale.
 Additionally, its manufacturing base in India enables LSL to offer high-quality, affordable eyewear to customers across global markets.
- LSL commenced its international operations in 2019 with an expansion into Singapore, marked by the launch of a website and one retail store. Since then, the company has steadily built its global presence across key regions, including Southeast Asia, Japan, and the Middle East. In August 2022, LSL acquired Owndays, a leading eyewear brand with a strong foothold in Japan and Southeast Asia. This acquisition has strengthened LSL's ability to offer affordable, high-quality prescription eyeglasses in markets witnessing a growing prevalence of refractive errors, as highlighted in the Redseer Report.
- During the three months ended June 30, 2025, and for FY25, LSL recorded 0.70 mn and 2.47 mn transacting customer accounts, respectively, in its international markets, with eyewear unit sales of 1.13 mn and 4.29 mn, respectively. As of June 30, 2025, the company operated 669 international stores, underscoring its strong retail footprint beyond India.
- India represents a rapidly expanding market for prescription eyewear, driven by increasing awareness, rising demand, and relatively low penetration of corrective vision solutions. According to the RHP, LSL's market share in the prescription eyewear segment stood at 4–6% in FY25. The number of individuals affected by refractive errors in India has grown from approximately 43% (around 590 mn people) in FY20 to about 53% (around 777 mn) in FY25, and is projected to reach 62% (around 943 mn) by FY30. To capture this growing opportunity, the company aims to bridge the gap in access to quality eyewear through continued omnichannel expansion and by strengthening its retail presence across metropolitan, Tier 1, and Tier 2+ cities in India.
- Leveraging its presence across 14 countries as of June 30, 2025, LSL has been able to share design collections globally, enabling the launch of innovative products tailored to local preferences while maintaining a unified global brand identity. During the three months ended June 30, 2025, and the financial year 2025, the company introduced 42 and 105 new in-house designed and engineered collections, respectively, including collaborations with leading brands and renowned celebrities.
- To ensure a superior customer experience, LSL has strategically centralized and retained control over its entire prescription eyeglasses supply chain encompassing lens manufacturing and edging, lens and frame design, frame production, and delivery. The company owns and operates advanced frame and lens design as well as prescription eyeglass manufacturing facilities in Bhiwadi (Rajasthan) and Gurugram (Haryana), supported by regional facilities in Singapore and the United Arab Emirates.
- This integrated and centralized manufacturing model in India enables LSL to offer high-quality prescription eyeglasses at affordable
 prices, with next-day delivery available in select locations. Moreover, by maintaining full control over its supply chain, the company
 can swiftly incorporate customer feedback into product innovation and service improvements. As per its RHP, LSL's Bhiwadi facility
 ranks among the top two vertically integrated and centralized manufacturing facilities for prescription eyeglasses globally, based on
 production capacity for the financial year 2025.
- LSL commenced its manufacturing operations in India in 2021 and produced 69.87% of its prescription eyeglasses sold during FY25 at its centralized facilities in the country. The company has significantly expanded its manufacturing capacity, with the annual installed capacity at its Bhiwadi facility increasing from 2.20 mn units as of March 31, 2023, to 14.27 mn units as of March 31, 2025.
- In December 2024, LSL signed a memorandum of understanding with the Government of Telangana to establish a new manufacturing facility in Hyderabad. This upcoming facility, which will be substantially larger than the existing 10.69-acre Bhiwadi plant, is designed to meet the company's growing domestic and international demand, while also enhancing operational resilience and mitigating manufacturing-related risks. As of FY25, LSL operated a total of 2,311 company-owned (CoCo) stores, comprising 1,823 in India and 488 in international markets. This reflects steady growth from 2,224 stores in FY24, 1,850 stores in FY23, and 1,419 stores in FY22. In addition to its CoCo network, the company also operates through franchisee, joint-venture, and company-owned franchise models, with a total of 495 such stores in FY25 including 314 in India and 181 overseas. In comparison, the franchise network stood at 499 stores in FY24, 539 in FY23, and 540 in FY22.

Particular	FY	′23	3 FY24		FY25		Q1FY25		Q1FY26	
Manufacturing Facility (in units)	Installed Capacity	Capacity Utilization (%)	Installed Capacity	Capacity Utilization (%)						
Gurugram	1,27,31,000	52.3%	1,27,31,000	44.5%	1,27,31,000	40.9%	31,83,000	36.9%	31,83,000	39.2%
Bhiwadi	21,95,000	19.9%	89,63,000	48.1%	1,42,67,000	54.3%	32,92,000	51.9%	38,41,000	68.3%
Singapore	2,72,000	27.6%	2,72,000	42.7%	3,05,000	54.4%	68,000	52.0%	76,000	61.9%
Dubai	-	-	-	-	1,48,000	22.2%	37,000	3.1%	37,000	40.6%
Total	1,51,98,000	47.2%	2,19,66,000	45.91%	2,74,51,000	47.93%	65,80,000	44.35%	71,37,000	55.10%

Financial statements:

Restated consolidated profit and loss statement (Rs. cr)								
	FY23	FY24	FY25	Q1FY25	Q1FY26	TTM	CAGR over FY23-25 A	Annual growth over FY24
Revenue from operations	3,788.0	5,427.7	6,652.5	1,520.4	1,894.5	7,026.5	32.5%	22.6%
Cost of raw material and components consumed	(1,132.8)	(1,482.9)	(1,760.3)	(395.0)	(512.3)	(1,877.7)	24.7%	18.7%
Purchases of stock in trade	(267.4)	(347.4)	(457.3)	(87.6)	(100.6)	(470.3)	30.8%	31.7%
Changes in inventory of traded	32.1	54.2	83.3	2.6	8.9	89.6	61.1%	53.7%
Gross profit	2,419.9	3,651.6	4,518.1	1,040.5	1,290.4	4,768.1	36.6%	23.7%
Employee benefit expenses	(717.6)	(1,086.5)	(1,378.8)	(293.7)	(465.6)	(1,550.7)	38.6%	26.9%
Other expenses	(1,438.6)	(1,891.7)	(2,163.9)	(562.8)	(488.8)	(2,089.8)	22.6%	14.4%
EBITDA	263.8	673.3	975.5	183.9	336.0	1,127.6	92.3%	44.9%
Depreciation & amortization expenses	(417.6)	(672.2)	(796.6)	(186.4)	(237.1)	(847.3)	38.1%	18.5%
EBIT	(153.8)	1.1	178.9	(2.5)	98.9	280.3		
Finance costs	(83.3)	(123.0)	(145.9)	(37.7)	(41.0)	(149.2)	32.4%	18.6%
Other income	139.9	182.2	356.8	43.3	51.6	365.1	59.7%	95.8%
PBT & share of associate and JV	(97.1)	60.3	389.8	3.1	109.5	496.2		546.7%
Share of (loss) of associates and joint ventures	(4.1)	(1.2)	(4.4)	(0.5)	0.6	(3.4)	4.4%	256.2%
PBT & Exceptional Items	(101.2)	59.0	385.4	2.6	110.1	492.8		552.8%
Exceptional Items	0.0	0.0	0.0	0.0	10.4	10.4		
РВТ	(101.2)	59.0	385.4	2.6	99.7	482.4		552.8%
Tax expenses	37.4	(69.2)	(88.0)	(13.6)	(38.5)	(113.0)		27.2%
Reported PAT	(63.8)	(10.2)	297.3	(11.0)	61.2	369.5		

	Restated	consolidate	d balance sh	eet statem	ent (Rs. cr)			
	FY23	FY24	FY25	Q1FY25	Q1FY26	TTM	CAGR over FY23- 25	Annual growth over FY24
Equity share capital	15.3	15.4	154.3	15.4	154.3	154.3	217.8%	901.0%
Instruments entirely equity in nature	17.2	167.0	167.1	167.1	167.1	167.1	211.4%	0.1%
Other Equity	5,441.3	5,466.9	5,777.3	5,604.8	5,894.4	5,894.4	3.0%	5.7%
Non-controlling interest	96.0	106.7	107.4	105.6	107.7	107.7	5.8%	0.7%
Non-current borrowings	573.8	268.1	211.5	247.0	199.2	199.2	-39.3%	-21.1%
Non-current lease liabilities	1,087.6	1,290.6	1,701.2	1,379.5	1,823.8	1,823.8	25.1%	31.8%
Other non-current financial liabilities	440.4	442.4	176.5	468.0	179.6	179.6	-36.7%	-60.1%
Provisions	62.3	65.9	92.0	67.1	94.6	94.6	21.5%	39.6%
Other non-current liabilities	43.3	46.9	63.6	45.8	60.2	60.2	21.1%	35.4%
Deferred tax liabilities	163.0	151.0	151.5	151.0	151.4	151.4	-3.6%	0.3%
Trade payables	577.2	516.2	740.0	501.1	789.7	789.7	13.2%	43.4%
Current borrowings	343.4	229.0	134.4	131.3	136.3	136.3	-37.4%	-41.3%
Current lease liabilities	353.6	388.0	525.6	417.8	576.1	576.1	21.9%	35.5%
Other current financial liabilities	95.2	102.0	92.9	110.6	129.4	129.4	-1.2%	-8.9%
Other current liabilities	145.9	191.9	272.5	212.0	244.2	244.2	36.7%	42.0%
Current Provisions	42.5	51.5	76.2	48.5	80.4	80.4	34.0%	48.0%
Other current liabilities	30.3	31.4	27.0	32.8	57.4	57.4	-5.7%	-14.2%
Total liabilities	9,528.3	9,531.0	10,471.0	9,705.6	10,845.7	10,845.7	4.8%	9.9%
	•	•		,	•	•		
Property, plant and equipment	721.2	945.3	1,340.5	928.1	1,374.3	1,374.3	36.3%	41.8%
Capital work-in-progress	133.7	70.8	106.9	77.7	118.9	118.9	-10.6%	50.9%
Investment Properties	679.0	966.3	-	1,044.5	-	-		
Goodwill	1,862.3	1,867.4	1,875.6	1,866.3	1,875.6	1,875.6	0.4%	0.4%
Other intangible assets	973.9	907.5	906.7	892.7	905.5	905.5	-3.5%	-0.1%
Intangible assets under development	0.2	-	-	-	-	-		
Right-of-use assets	831.0	814.4	2,108.5	852.3	2,267.6	2,267.6	59.3%	158.9%
Investment account using the equity method	23.6	26.6	31.3	26.0	22.8	22.8	15.1%	17.8%
Invetments	13.0	15.1	18.7	15.1	18.7	18.7	20.0%	24.1%
Other financial assets	217.2	360.9	250.4	232.2	309.6	309.6	7.4%	-30.6%
Deferred tax assets	66.0	44.5	81.5	51.0	93.8	93.8	11.1%	83.3%
Non current tax assets (net)	31.5	31.5	70.6	18.7	59.0	59.0	49.8%	124.0%
Other non-current assets	62.3	43.5	50.3	41.7	107.7	107.7	-10.2%	15.6%
Inventories	611.2	688.1	1,081.4	626.2	1,157.6	1,157.6	33.0%	57.2%
Invetments	751.4	961.6	987.8	1,073.9	1,043.7	1,043.7	14.7%	2.7%
Trade receivables	281.1	341.4	125.9	346.6	138.9	138.9	-33.1%	-63.1%
Cash & cash equivalents	334.4	302.1	654.2	461.1	605.0	605.0	39.9%	116.5%
Other bank balances	652.3	503.1	210.7	98.3	327.0	327.0	-43.2%	-58.1%
Other current financial assets	1,074.5	428.7	279.9	842.4	124.5	124.5	-49.0%	-34.7%
Other current assets	208.6	212.3	290.1	210.9	295.7	295.7	17.9%	36.6%
Total assets	9,528.3	9,531.0	10,471.0	9,705.6	10,845.7	10,845.7	4.8%	9.9%

Source: Choice Equity Broking

Restated consolidated cash flow statement (Rs. cr)								
	FY23	FY24	FY25	Q1FY25	Q1FY26	ттм	CAGR over FY23-25	Annual growth over FY24
Cash flow before working capital changes	280.5	711.1	1,028.0	210.4	354.4	1,172.0	-9.2%	-79.5%
Working capital changes	(162.2)	(165.6)	308.4	63.2	(64.8)	180.4	-173.0%	-79.5%
Cash flow from operating activities	94.7	487.4	1,230.6	269.3	283.3	1,244.6	41.7%	-78.1%
Purchase of PP&E	(398.8)	(430.6)	(416.4)	(66.5)	(156.5)	(506.4)	-45.0%	-84.0%
Cash flow from investing activities	(2,976.5)	158.7	(265.9)	(41.4)	(166.4)	(390.8)	-75.9%	-84.4%
Cash flow from financing activities	2,776.7	(721.8)	(534.8)	5.2	(193.8)	(733.8)	-87.6%	-101.0%
Net cash flow	(105.0)	(75.7)	430.0	233.1	(76.8)	120.0	-230.4%	-45.8%
Opening balance of cash	6.4	291.8	220.0	220.0	654.2	654.2	224.8%	0.0%
Cash and cash equivalent of acquired subsidiary	390.5	4.2	5.4	0.0	0.0	5.4		
Effect of movement in exchange rates of cash held in Foreign Subsidiaries	0.0	(0.3)	(1.2)	8.0	27.5	18.4		
Closing balance of cash from continuing operations	291.8	220.0	654.2	461.1	604.8	798.0	16.5%	-29.5%

		Financial rat	ios				
Particulars	FY23	FY24	FY25	Q1FY25	Q1FY26	CAGR over FY23-25	Annual growth over FY24
		Profitability ra	tios				
Revenue growth rate	-	43.3%	22.6%	-	24.6%	-	(2,072) bps
Gross profit growth rate	-	50.9%	23.7%	-	24.0%	-	(2,717) bps
Gross profit margin	63.9%	67.3%	67.9%	-	68.1%	403 bps	64 bps
EBITDA growth rate	-	155.3%	44.9%	-	82.7%	-	-
EBITDA margin	7.0%	12.4%	14.7%	-	17.7%	770 bps	226 bps
EBIT growth rate	-	0.0%	0.0%	-	0.0%	-	-
EBIT margin	-4.1%	0.0%	2.7%	-	5.2%	675 bps	267 bps
Reported PAT growth rate	-	0.0%	0.0%	-		-	-
Reported PAT margin	-1.7%	-0.2%	4.5%	-	3.2%	615 bps	466 bps
		Turnover rat	ios				
Inventory receivable turnover ratio	6.2	8.4	7.5	1.8	2.1	10.1%	-10.0%
Trade receivable turnover ratio	13.5	17.4	28.5	6.4	7.8	45.4%	63.3%
Accounts payable turnover ratio	6.6	9.9	10.6	2.5	2.9	27.0%	6.7%
Fixed asset turnover ratio	1.1	1.5	1.5	0.4	0.4	14.6%	1.7%
Total asset turnover ratio	0.4	0.6	0.6	0.2	0.2	26.4%	11.6%
		Cash Convers	ion				
Inventories days	59	44	49	51	42	-9.2%	11.1%
Trade receivables days	27	21	13	14	12	-31.2%	-38.8%
Trade payables days	(55.6)	(36.8)	(34.5)	(36.7)	(30.7)	-21.3%	-6.3%
Cash conversion cycle	30	28	27	28	23	-5.9%	-3.4%
		Liquidity rati	os				
Current ratio	2.5	2.3	1.9	2.5	1.8	-11.2%	-14.7%
Quick ratio	1.6	1.2	0.8	1.3	0.7	-27.9%	-29.4%
Total debt	2,894.0	2,720.3	2,842.2	2,754.2	3,044.3	-0.9%	4.5%
Net debt	2,559.6	2,418.1	2,188.0	2,293.2	2,439.3	-7.5%	-9.5%
Debt to equity	0.5	0.5	0.5	0.5	0.5	-6.1%	-3.2%
		Cash flow rat	ios				
CFO to PAT	(1.5)	(48.0)	4.1	(24.6)	4.6	-	-108.6%
CFO to Capex	0.2	1.1	3.0	4.1	1.8	252.7%	161.1%
CFO to total debt	0.0	0.2	0.4	0.1	0.1	263.7%	141.7%
		Return ratio	S				
RoIC (%)	-1.7%	0.0%	2.2%	0.2%	1.0%	392 bps	221 bps
RoE (%)	-1.2%	-0.2%	4.9%	-0.2%	-0.2%	604 bps	506 bps
RoA (%)	-0.7%	-0.1%	2.8%	-0.1%	-0.1%	351 bps	295 bps
RoCE (%)	-1.8%	0.0%	2.1%	0.0%	1.1%	389 bps	204 bps
		Per Share da					
Restated EPS (Rs.)	(0.4)	(0.1)	1.7	(0.1)	0.4	-	-
BVPS (Rs.)	31.6	32.6	35.2	33.4	35.8	5.6%	8.0%
Operating cash flow per share (Rs.)	0.5	2.8	7.1	1.6	1.6	260.4%	152.5%

Source: Choice Equity Broking

IPO rating rationale

Subscribe: An IPO with strong growth prospects and valuation comfort.

Subscribe for Long Term: Relatively better growth prospects but with valuation discomfort.

Avoid: Concerns on both fundamentals and demanded valuation.

Research disclaimer & disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Choice Equity Broking Pvt. Ltd. ("CEBPL") is a registered Research Analyst Entity (Reg. No. INH000000222; Cin. No. U65999MH2010PTC198714). Registered Address: Sunil Patodia Tower, J B Nagar, Andheri (East), Mumbai 400-099. Tel. No. 022-6707 9999.

Compliance Officer: Prashant Salian; Tel. No. 022-6707-9999; Ext. 2310; email-id: compliance@choiceindia.com Grievance officer: Deepika Singhvi ; Tel. No. 022-6707-9999; Ext. 834; email-id: ig@choiceindia.com

Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors .

This Research Report (hereinafter referred as "Report") has been prepared by Choice Equity Broking Pvt. Ltd. as a Research Entity (hereinafter referred as "CEBPL RE"). The Research Analysts, strategists are principally responsible for the preparation of "CEBPL RE" research. The research analysts have received compensation based upon various factors, which may include quality of research, investor client feedback, stock picking, competitive factors and firm revenues etc.

Whilst CEBPL has taken all reasonable steps to ensure that this information is correct, CEBPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his/her own risk and CEBPL does not accept any liability as a result. Securities and derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance.

General disclaimer: This 'Report' is strictly meant for use by the recipient and is not for circulation. This Report does not take into account particular investment objectives, financial situations or specific needs of individual clients nor does it constitute a personal recommendation. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through CEBPL nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this "Report" should rely on information/data arising out of their own study/investigations. It is advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This 'Report' has been prepared on the basis of publicly available information, internally developed data and other sources believed by CEBPL to be reliable. CEBPL or its directors, employees, affiliates or representatives shall not be responsible for, or warrant for the accuracy, completeness, adequacy and reliability of such information / opinions / views. Though due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of CEBPL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report.

The price and value of the investments referred to in this Report and the income from them may tend to go down as well as up, and investors may incur losses on any investments. Yester performance shall not be a guide for future performance. CEBPL does not provide tax advice to its clients, and all investors are strongly advised to take advice of their tax advisers regarding taxation aspects of any potential investment. Opinions are based on the current scenario as of the date appearing on this 'Report' only. CEBPL does not undertake to advise you as to any change of our views expressed in this "Report' may differ on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold CEBPL, its employees and associates responsible for any losses, damages of any type whatsoever.

Disclaimers in respect of jurisdiction: This Report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject "CEBPL RE" to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by "CEBPL RE" in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this 'Report' shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. "CEBPL" requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to "CEBPL". Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in Mumbai (India).

Statements on ownership and material conflicts of interest, compensation - CEBPL and Associates reciprocates to the best of the knowledge and belief of CEBPL/ its Associates/research Analyst who is preparing this Report.

Disclosures of interest (Additional):

- 1) "CEBPL", its research Analyst(s), or its associates or relatives of the Research Analyst does not have any financial interest in the company (ies) covered in this Report.
- 2) "CEBPL" its research Analyst, or its associates or relatives of the research analyst affiliates collectively do not hold more than one of the securities of the company (ies) covered in this Report as of the end of the month immediately preceding the distribution of the research report.
- 3) "CEBPL", its research analyst, his/her associate, his/her relative, do not have any other material conflict of interest at the time of publication of this Report.
- 4) "CEBPL", its research analyst, and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company (ies) covered in this Report, in the past twelve months.
- 5) "CEBPL", its research analyst, or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in this Report.
- 6) "CEBPL, or its associates have not received compensation or other benefits from the company (ies) covered in this Report or from any third party, in connection with the Report.
- 7) CEBPL research analyst has not served as an Officer, Director, or employee of the company (ies) covered in the Report.
- 8) "CEBPL", its research analyst has not been engaged in market making activity for the company (ies) covered in the Report.

Details of Associates of CEBPL and Brief History of Disciplinary action by regulatory authorities are available on our website i.e. https://choiceindia.com/research-listing.

Research disclaimer & disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 (Contd...)

The details of CEBPL, its research analyst and its associates pertaining to the companies covered in the Report are given below:

Sr. no.	Particulars Particulars	Yes / No
1.	Whether compensation has been received from the company (ies) covered in the Research report in the past 12 months for investment banking transaction by CEBPL	No
2	Whether Research Analyst, CEBPL or its associates or relatives of the Research Analyst affiliates collectively hold more than 1% of the company (ies) covered in the Research report	No
3.	Whether compensation has been received by CEBPL or its associates from the company (ies) covered in the Research report	No
4.	CEBPL or its affiliates have managed or co-managed in the previous twelve months a private or public offering of securities for the company (ies) covered in the Research report	No
5.	CEBPL, its research analyst, his associate, or its associates have received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company (ies) covered in the Research report, in the last twelve months	No

Copyright: The copyright in this research report belongs exclusively to CEBPL. All rights are reserved. Any unauthorized use or disclosure is prohibited. No reprinting or reproduction, in whole or in part, is permitted without the CEBPL's prior consent, except that a recipient may reprint it for internal circulation only and only if it is reprinted in its entirety.

This "Report" is for distribution only under such circumstances as may be permitted by applicable law. This "Report" has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This "Report" is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither CEBPL nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this "report" or lack of care in this report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Information barriers may be relied upon by CEBPL, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of CEBPL.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States. The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by CEBPL with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior written consent of CEBPL and CEBPL accepts no liability whatsoever for the actions of third parties in this respect.